PhaseV, a leader in AI/ML-driven clinical development, today announced the completion of a $50 million Series A funding round ...

BOSTON, April 8, 2025 /PRNewswire/ -- PhaseV, a leader in AI/ML-driven clinical development, today announced its participation in several upcoming biotech and data science conferences. The company ...

About PhaseV PhaseV is developing advanced AI/ML solutions to optimize clinical development. Biopharma sponsors and CROs are leveraging PhaseV's platform to rapidly design and execute adaptive ...

Moderated by Brad Carlin PhD, Senior Director, Data Science and Statistics at PhaseV, the panel will discuss: AI-driven approaches for smarter patient selection to optimize recruitment and site ...